REACH - Non-regulatory announcement*
18 July 2024
Fusion Antibodies
plc
("Fusion"
or the "Company")
Launch of New Interactive
Investor Hub
Enabling
proactive communication and
enquiry support to
shareholders
Fusion Antibodies plc (AIM: FAB), specialists
in pre-clinical antibody discovery, engineering and supply for both
therapeutic drug and diagnostic applications, announces
the launch of its new interactive investor hub which is
accessible from the Company's website.
For both existing and prospective shareholders,
the new interactive investor hub brings all of the Company's
existing content into a single integrated platform, and will enable
investors and stakeholders to be better informed and engaged,
including but not limited to, the Company's:
● Regulatory
announcements
● Reports
●
Presentations
● Educational
material
● Interviews
● Corporate
research
The new investor hub also offers an interactive
online experience, enabling the Company's stakeholders to comment
on and ask the Fusion team questions via a dedicated portal which
the Company will monitor and through which it will provide
appropriate responses in a timely manner.
To sign up to the new interactive investor hub,
stakeholders are encouraged to:
1. Visit
investorhub.fusionantibodies.com
2. Follow the prompts to sign
up for an investor hub account
3. Complete your account
profile
The information disclosed pursuant to Rule 26
of the AIM Rules for Companies will continue to be available at the
Company's website: www.fusionantibodies.com.
Adrian
Kinkaid, CEO
of Fusion Antibodies plc, commented: "Engaging with our shareholders has always been fundamental at
Fusion. The launch of our new interactive investor hub marks an
exciting step forward, providing a dynamic platform for current and
potential investors to connect with us as well as to gain a
comprehensive understanding of our mission, our technology and our
business.
"The new
interactive investor hub will act as a rich resource, offering
video content, detailed information, and insights into our ongoing
activities and future strategies. We encourage our stakeholders to
explore the new investor hub and share their thoughts as we aim to
enhance and refine our communication channels."
Enquiries:
|
Fusion
Antibodies plc
|
www.fusionantibodies.com
|
|
Adrian Kinkaid, Chief Executive
Officer
Stephen Smyth, Chief Financial
Officer
|
Via Walbrook
PR
|
|
|
|
|
Allenby
Capital Limited
|
Tel: +44 (0) 20 3328
5656
|
|
James Reeve/Vivek Bhardwaj (Corporate
Finance)
Tony Quirke/Joscelin Pinnington (Sales and
Corporate Broking)
|
|
|
|
|
|
|
|
|
Shard Capital
Partners LLP
|
|
|
Damon Heath (Joint Broker)
|
Tel: +44 (0) 207 186
9952
|
|
|
|
|
|
|
|
Walbrook
PR
|
Tel: +44 (0)20 7933 8780
or fusion@walbrookpr.com
|
|
Anna Dunphy
|
Mob: +44 (0)7876 741 001
|
|
|
| |
About Fusion
Antibodies plc
Fusion is a Belfast based contract research
organisation ("CRO") providing a range of antibody engineering
services for the development of antibodies for both therapeutic
drug and diagnostic applications.
The Company's ordinary shares were admitted to
trading on AIM on 18 December 2017. Fusion provides a broad range
of services in antibody generation, development, production,
characterisation and optimisation. These services include antigen
expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary
CDRx TM platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin
out from Queen's University Belfast. The Company's mission is to
enable pharmaceutical and diagnostic companies to develop
innovative products in a timely and cost-effective manner for the
benefit of the global healthcare industry. Fusion Antibodies
provides a broad range of services in antibody generation,
development, production, characterisation and
optimisation.
Fusion Antibodies growth strategy is based on
combining the latest technological advances with cutting edge
science to deliver new platforms that will enable Pharma and
Biotech companies get to the clinic faster, with the optimal drug
candidate and ultimately speed up the drug development
process.
*About Reach
announcements
This is a Reach announcement. Reach
is an investor communication service aimed at assisting listed
and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases
into the public domain. Information required to be notified
under the AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on Reach.